XSTO
ACE
Market cap9mUSD
Oct 09, Last price
0.86SEK
1D
0.47%
1Q
29.52%
IPO
-97.07%
Name
Ascelia Pharma AB
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
33.99%
Rev. gr., 5y
%
Revenues
0
Net income
-76m
L-4.72%
CFO
-72m
L+14.97%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Ascelia Pharma AB (publ) is a Swedish biotechnology company concentrating on the development of orphan drugs for cancer treatment. The firm is currently progressing Mangoral, an innovative non-gadolinium contrast agent, through Phase 3 clinical trials for magnetic resonance imaging (MRI) of the liver. Furthermore, it is advancing Oncoral, a novel oral chemotherapy tablet, which is in Phase 2 development for gastric cancer therapy. Ascelia Pharma has also entered into a clinical collaboration agreement with Taiho Oncology, Inc. to develop Oncoral in combination with LONSURF. The company was established in 2000 and has its headquarters situated in Malmö, Sweden.
Key people
Dorthe da Graca Thrige
Chief Operating Officer · since 2014
Julie Waras Brogren
Chief Commercial Officer · since 2020
Magnus O. Corfitzen
Chairman of the Board
Niels Mengel
Director · since 2000
Rene Spogard
Director · since 2017
Headquarters & legal address
Hyllie Boulevard 34
Malmö, M 215 32
SE
Malmö, M 215 32
SE
Address
Hyllie Boulevard 34
Malmo, M 215 32
SE
Malmo, M 215 32
SE
Previous name
CMC Contrast Aktiebolag
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||